Advanced glycation end products in pregnancies complicated with diabetes mellitus or preeclampsia

Hypertension in Pregnancy

Volumn 27, Issue 4, 2008, Pages 374-386

  Harsem, Nina K ^a   Braekke, Kristin ^a   Torjussen, Tale ^a   Hanssen, Kristian ^b   Staff, Anne Cathrine ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

AGE; Diabetes mellitus; Oxidative stress; Preeclampsia; Pregnancy

Indexed keywords

8 ISOPROSTANE; ADVANCED GLYCATION END PRODUCT; ALPHA TOCOPHEROL; ANTIOXIDANT; INSULIN;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD CHEMISTRY; BLOOD SAMPLING; CHEMICAL ANALYSIS; CIRCULATION; CONTROLLED STUDY; ENZYME ANALYSIS; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MATERNAL BLOOD; OXIDATIVE STRESS; PREECLAMPSIA; PREGNANCY; PREGNANCY DIABETES MELLITUS; PREGNANT WOMAN;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DIABETES, GESTATIONAL; DINOPROST; FEMALE; FERRIC COMPOUNDS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LYSINE; OXIDATIVE STRESS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY IN DIABETICS; VITAMIN E; YOUNG ADULT;

EID: 56049107292     PISSN: 10641955     EISSN: 15256065     Source Type: Journal    
DOI: 10.1080/10641950802000968     Document Type: Article

References (34)

1. Kaaja R. Insulin resistance syndrome in preeclampsia. Semin Reprod Endocrinol 1998;16:41-46.
2. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidative stress in atherothrombotic disease. Atheroscler Thromb Vasc Biol 1997;17:2309-2315.
3. Schram MT, Chaturvedi N, Schalkwijk C, Giorgino F, Ebeling P, Fuller JH. Vascular risk factors and markers of endothelial function as determinants of inflammator markers in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care 2003;26:2165-2173.
4. Garner PR, D'Alton ME, Dudley DK, Huard P, Hardie M. Preeclampsia in diabetic pregnancies. Am J Obstet Gynecol 1990;163:505-508.
5. Roberts JM, Redman CW. Pre-eclampsia: more than pregnancy- induced hypertension. Lancet 1993;341:1447-1451.
6. Berg TJ, Bangstad HJ, Torjesen PA, Osterby, Bucala R, Hanssen KF. Advanced glycation end products in serum predicts changes in the kidney morphology of patients with insulin-dependent diabetes mellitus. Metabolism 1997;46:661-665.
7. Brownlee M, Cerami A, Vlassara H. Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular disease. Diab Metab Rev 1988;4:437-451.
8. Dyer D, Dunn JA, Thorpe SR, Bailie KE, Lyons TJ, McCane DR, Baynes JW. Accumulation of Maillard products in skin collagen in diabetes and aging. J Clin Inves 1993;91:2463-2469.
9. Horie K, Miyata T, Maeda K, Miyata S, Sugiyama S, Sakai H, Strihou CY, Monnier VM, Witzum JL. Immunohistochemical colocalization of glucoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glucoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest 1997;100:2995-3004.
10. Baynes JW, Thorpe SR. Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 2000;28:1708-1716.
11. Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW. N epsilon-(carboxymethyl) lysine is a dominating advanced glycation end product (AGE) antige in tissue proteins. Biochem 1995;34:10872-10878.
12. Chekir C, Nakatsuka M, Noguchi S, Konishi H, Kamada Y, Sasaki A, hao L, Hiramatsu Y. Accumulation of advanced glycation end products in women with preeclampsia: Possible involvement of placental oxidative and nitrative stress. Placenta 2006;27:225-233.
13. Buongiorno AM, Morelli S, Sagratella E, Castaldo P, Di Virgilio A, Maroccia E, Fallucca F, Sensi M. Levels of advanced glycation end products (AGE) in sera of pregnant diabetic women: comparison between type 1, type 2 and gestational diabetes mellitus. Ann Ist Super Sanità 1997;33:375-378.
14. Hubel CA. Oxidative stress in the pathogenensis of preeclampsia. Proc Soc Exp Biol Med 1999;222:222-235.
15. Walsh SW. maternal-placental interactions of oxidative stress and antioxidants in preeclampsia. Semin Reprod Endocrinol 1998;16:93-104.
16. Staff AC, Halvorsen B, Ranheim T, Henriksen T. Elevated level of free 8-iso-prostaglandin F2alpha in the decidua basalis of women with preeclampsia. Am J Obstet Gynecol 1999;181:1211-1215.
17. Roberts LJ, Morrow JD. Measurement of F(2)-isoprostanes as an index of Oxidative stress in vivo. Free Radic Biol Med 2000;28:505-513.
18. Llurba E, Gratacos E, Martin-Gallan P, Cabero L, Dominguez C. A Comprehensive study of oxidative stress and antioxidant status in preeclampsia and normal pregnancy. Free Radical Biol Med 2004;37:557-570.
19. Barden A, Ritchie J, Walters B, Michael C, Rivera J, Mori T, Croft K, Beilin L. Study of plasma factors associated with neutrophil activation and lipid peroxidation in preeclampsia. Hypertens 2001;38:803-808.
20. Harsem NK, Braekke K, Staff AC. Augmented oxidative stress as well as antioxidant capacity in maternal circulation in preeclampsia. Eur J Obstet Gynecol Reprod Biol 2005, e-pub ahead of press.
21. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes Mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med 1998;15:539-553.
22. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 2002;77:67-75.
23. Nourooz-Zadeh J, Gopaul NK, Barrow S, Mallet AI, Anggard EE. Analysis of F2-isoprostanes as indicators of non-enzymatic lipid peroxidation in vivo by Gas chromatography-mass spectrometry: development of a solid-phase Extraction procedure. J Chromatogr B Biomed Appl 1995;667:199-208.
24. Makita Z, Vlassara H, Cerami A, Bucala R. Immunochemical detection of Advanced glycosylation end products in vivo. J Biol Chem 1992;267:5133-8.
25. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a Measure of "antioxidant power": the FRAP assay. Anal Biochem 1996;239:70-76.
26. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315-1321.
27. Schalkwijk CG, Ter Wee PM, Stehouwer CD. Plasma levels of AGE peptides in type1 diabetes patients are associated with serum creatinine and not with albumin excretion rate: possible role of AGE peptide-asscociated endothelial dysfunction. Ann N Y Acad Sci 2005;1043:662-670.
28. Kousta E, Lawrence N, Penny A, Millauer B, Cela E, Robinson S, Johnson D. Abnormalities of glucose tolerance and cardiovascular risk factors following Gestational diabetes and their association with ethnic origin. Diabetes 2000;49:A188.
29. Damm P. Gestational diabetes mellitus and subsequent development of overt Diabetes mellitus - a clinical, metabolic and epidemiological study. Dan Med Bull 1998;45:495-509.
30. Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS; Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005;352:2477-2486.
31. Waltenberger J. Growth factor signal transduction defects in the cardiovascular system. Cardiovasc Res 2005;65:574-580.
32. Lappas M, Permezel M, Rice GE. Advanced glycation endproducts mediate pro-inflammatory actions in human gestational tissues via nuclear factor-κB and extracellular signal-regulated kinase 1/2. J Endocrinol 2007;193:269-277.
33. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996;19:257-267.
34. Kharb S. Lipid peroxidation in pregnancy with preeclampsia and diabetes. Gynecol Obstet Invest 2000;50:113-116.